IDXX

IDEXX Laboratories is set to report Q3 2026 results on November 2, with consensus estimates projecting 7.5% revenue growth to $1.19 billion and 9.1% EPS growth to $3.71. The company's Companion Animal Group diagnostics, Water segment, and Livestock/Poultry/Dairy divisions are expected to drive performance, supported by volume growth and recurring revenues. IDEXX carries a Zacks Rank #2 with a +0.59% Earnings ESP, suggesting potential to beat estimates.

The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat earnings estimates by comparing analyst revisions. When combined with a Zacks Rank #3 or stronger, stocks posted positive surprises 70% of the time with ~28% average annual returns. Two medical stocks highlighted as examples are Veracyte (VCYT) with a +4.65% ESP and Idexx Laboratories (IDXX) with a +0.59% ESP, both positioned to potentially beat their upcoming earnings reports.

Idexx Laboratories (IDXX), an animal diagnostic and healthcare company, shows strong potential for another earnings beat. The company has consistently exceeded earnings estimates in recent quarters with an average surprise of 4.78%. With a positive Earnings ESP of +0.59% combined with a Zacks Rank #2 (Buy) rating, analysts predict a high probability of beating consensus estimates in the upcoming November 2, 2026 earnings report.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their upcoming earnings reports. Idexx Laboratories (IDXX) holds a #2 Buy rating with a +0.59% ESP ahead of its November 2, 2026 earnings release, while Iovance Biotherapeutics (IOVA) has a #3 Hold rating with a +22.22% ESP before reporting on November 5, 2026. Both stocks show promise for positive earnings surprises based on the Zacks ESP methodology.

Idexx Laboratories (IDXX) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The upgrade reflects improved earnings outlook that could drive buying pressure and stock price increases. Analysts have steadily raised estimates for the company over the past three months, with a 0.8% increase in the Zacks Consensus Estimate.

ResMed is set to report Q1 fiscal 2027 results on October 29, with revenues projected at $1.39 billion (up 4%) and EPS expected to rise 4.7% to $2.67. The Sleep and Breathing Health segment is anticipated to grow 6.4% driven by device demand and new product launches, while Residential Care Software revenues are expected to decline 12.7% following the September 2026 sale of MatrixCare to Frazier Healthcare Partners. The company has a Zacks Rank #3 with a negative Earnings ESP of -0.60%.

Europe's companion animal diagnostics market is projected to reach US$2.27 billion by 2031, growing at a 9.5% CAGR from 2024-2031. Growth is driven by AI-enabled testing, preventive pet care adoption, technological advancements, and rising pet insurance uptake.

Germany and the UK lead the market, with veterinary hospitals and clinics as the largest end-user segment. Key players are investing in product development and AI integration to enhance diagnostic capabilities.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.